Navigation Links
Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
Date:2/9/2011

CRANBURY, N.J., Feb. 9, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced the dosing of the first subject in a Phase 2 clinical trial designed to evaluate the co-administration of its investigational drug Amigal™ (migalastat hydrochloride) with enzyme replacement therapy (ERT) for Fabry disease.  This open-label Phase 2 study is investigating drug-drug interactions between Amigal and the ERTs Fabrazyme® and Replagal®.  Preclinical studies have demonstrated that coadministration of Amigal results in a prolonged circulating half-life of ERT, increased enzyme activity in cells, and greater substrate reduction in target tissues compared to that seen with ERT alone.  Amigal is being developed in collaboration with GlaxoSmithKline (GSK), as part of an alliance between GSK Rare Diseases and Amicus.

John F. Crowley, Chairman and CEO of Amicus, stated "The commencement of this clinical study is an important milestone for Amicus and for pharmacological chaperone technology.  Based on encouraging preclinical results we believe the co-administration of Amigal with ERT has the potential to provide significant benefit for people with Fabry disease.  The advancement of this approach is a part of our vision to provide two new treatment options for Fabry patients in the future—Amigal as a monotherapy or Amigal co-administered with ERT.  Finally, we also believe this study will provide us with valuable proof of concept for applying this approach to other lysosomal storage diseases and more broadly to other indications treated with therapeutic proteins."  

Phase 2 Study Design

The Phase 2 trial will evaluate the safety and pharmacokinetics of Amigal and ERT when co-administered in 18 male patients with Fabry disease, ages 18-65, who have been receiving ERT for at least one month bef
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... announced that interim chief executive officer Howie Rosen ... and chief financial officer Tim Morris will ... of the two presentations are as follows: ...
(Date:5/21/2015)... DUBLIN , May 21, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/5x377m/north_american ) has announced the addition of ... by Type (Ankle Replacement, Digit Replacement, Elbow ... - Forecast to 2019" report to ... market for knee replacement was valued at ...
(Date:5/21/2015)... May 21, 2015 Research ... addition of the "North American Active Wound ... Application (Surgical Wound, & Ulcer), by End-User (In-Patient, ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... is estimated to grow at a CAGR of ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2
... ViaCyte, Inc. today announced the appointment ... Research and Development, reporting to John West, President and ... oversee all device development and manufacturing activities, including design, ... regulatory matters in the device area and to the ...
... Ohio, June 15, 2011 EndoSphere Inc. , ... international issued and pending patents, announced today that the ... a patent covering the use of its endoscopically implantable ... and type 2 diabetes. U.S. Patent number ...
Cached Medicine Technology:ViaCyte Names Michael Scott Vice President, Device Research & Development 2EndoSphere Inc. Receives Patent for Obesity Treatment 2
(Date:5/23/2015)... Baltimore, MD (PRWEB) May 23, 2015 Injury ... moratorium that has been passed by the Maryland legislature but ... , “The Maryland General Assembly passed HB 449 ... the Governor has not signed it into law. This bill ... 2017. Evidence is growing that demonstrates the danger of fracking ...
(Date:5/22/2015)... Mountain Point Medical Center, a campus of Jordan ... Friday, May 29, 2015 at 11 a.m., followed by a ... medical center, set to officially open on June 1, 2015, ... , “The opening of Mountain Point Medical Center is ... community,” said Kent Loosle, CEO of Mountain Point Medical Center. ...
(Date:5/22/2015)... Omar Ahmad Barrada, a junior at Milton ... 2015 Congress of Future Medical Leaders in Boston, Mass. ... “America’s highest achieving high school students.” , “I’m excited ... goals and learn better study habits,” said Omar. “The ... we can ask the surgeons questions.” , The goal ...
(Date:5/22/2015)... Family, friends, students, colleagues, mentors and fellow physicians ... D. Leffall, on Monday, May 18, with an 85th ... in the hospital’s Tower Auditorium. Leffall’s younger sister, 83-year-old ... to keep the secret. “I’d like to go in ... know something is up,” she said. , After more ...
(Date:5/22/2015)... 22, 2015 According to a new Aegis ... are equally as likely to worry about what will happen ... X, 77% Boomers, 69% Silent Generation), which may help explain ... scared of aging, particularly Millennials (47%), Gen X’ers (51%), and ... in April, 2015 among more than 2,000 U.S. adults ages ...
Breaking Medicine News(10 mins):Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3
... Kelly Clarkson has revealed that the reason behind her battle with ... winner admitted that she is struggling with the sleep disorder, because ... singer said that most of her lyrics and hits strike her ... added that she has to write them down or record them ...
... to whom? To the mother or to the nursing home? ... Johnson of Clark County in Nevada, USA, has ruled in ... preliminary injunction, ordering Sunrise Hospital and Medical Center in southern ... ,The hospital had refused to give the uterine ...
... DNA of 486 AIDS patients appear to play a role in ... Thursday. ,The researchers hope their finding will lead to ... more of these genes, and help the body's own immune system ... the scientists said in a study to appear in the Friday ...
... the good times are over. As Cte d'Ivoire's (Ivory Coast) ... start withdrawing, the government has restarted its medical care. ... ,"[In conflict zones] communities benefited from free health ... Jean Denoman, deputy director general at the Ministry of Health ...
... lives of fish. ,The 28-year-old gave up meat ... extinction of fishes. ,"I read that if we fish ... fish left, which is pretty soon. So it's a statement," Contactmusic ... that that she felt a 'strong connection' with nature now that ...
... to ask the government of India.,Clearly positing development against environment, ... so-called Green Bench that sits over environmental issues. ... Forest Advisory Committee (FAC), constituted under the Forest Conservation Act, ... its Green Bench on the ground that it has outlived ...
Cached Medicine News:Health News:Mother Has the Right to the Placenta, US Court Rules 2Health News:Mother Has the Right to the Placenta, US Court Rules 3Health News:Three Gene Variants Could Hold Key for HIV Vaccine: Study 2Health News:Good Times Over For Ivory Coasts Ill 2Health News:Indian Government Asks the Supreme Court to Keep Off Environmental Issues 2Health News:Indian Government Asks the Supreme Court to Keep Off Environmental Issues 3Health News:Indian Government Asks the Supreme Court to Keep Off Environmental Issues 4
... steroid produced in the adrenal gland and ... except as a precursor molecule. In the ... cortisol by the sequential actions of 21-hyroxylase ... and ovaries, 17alpha-OH-P can be converted to ...
... PC1200 Platelet Incubators bring precise ... counter top. These compact units ... have the security of a ... taking up a large amount ...
The PC4200i is the largest capacity platelet incubator available. It features a built-in agitator with a capacity of 396 random bags (132 apheresis)....
... Platelet incubators hold rotators and ... temperature can be set at ... 15C to 40C (59F to ... from top to bottom. Recorder ...
Medicine Products: